BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://futurebloodtesting.org
X-WR-CALDESC:Events for 
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20241015T120000
DTEND;TZID=Europe/London:20241015T130000
DTSTAMP:20260405T180015
CREATED:20240930T105934Z
LAST-MODIFIED:20241011T144659Z
UID:1894-1728993600-1728997200@futurebloodtesting.org
SUMMARY:Alzheimer’s disease Diagnosis and Plasma phospho-tau217-the ADAPT study
DESCRIPTION:Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-10-15 \n\nAbstract: Exciting progress is being made in the early and accurate detection of Alzheimer’s disease (AD) using blood tests. The most promising of these blood markers is plasma p-tau217. Dr Ashvini Keshavan will first review the evidence for concordance of plasma p-tau217 with gold standard Alzheimer’s disease biomarkers (i.e. amyloid positron emission tomography and cerebrospinal fluid tests) and the current state of commercial availability of plasma phosphorylated tau biomarkers including comparisons of effect sizes. She will then proceed with describing the plan for ADAPT\, a three-stage study including a UK multi-centre randomised controlled trial of disclosure of plasma p-tau217 results to patients and clinicians. From this study she aims to find out whether plasma p-tau217 helps to diagnose AD more quickly\, more accurately and at an earlier disease stage in comparison to routine memory clinic diagnostic pathways\, and we will obtain evidence for its cost effectiveness and acceptability to patients.\n\nBio: Dr Ashvini Keshavan is a senior clinical research fellow and honorary consultant neurologist at the Dementia Research Centre\, UCL Queen Square Institute of Neurology. A graduate of Trinity College\, Cambridge\, she completed postgraduate neurology training in London\, and obtained her PhD in 2019 on Cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Her ongoing work examines these biomarkers in clinical and pre-clinical cohorts\, aiming toward future application in more real-world settings\, serving diverse populations. She is the joint primary investigator for the UK-wide ADAPT (Alzheimer’s disease Diagnosis and Plasma p-Tau217) study.\n\nThis webinar is part of the 2024 Future Blood Testing Network+ webinar series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.
URL:https://futurebloodtesting.org/event/alzheimers-disease-diagnosis-and-plasma-phospho-tau217-the-adapt-study/
LOCATION:Online
CATEGORIES:Online Event,Seminar
ATTACH;FMTTYPE=image/jpeg:https://futurebloodtesting.org/wp-content/uploads/2024/09/FBTN-Webinar-Ash-1.jpg
ORGANIZER;CN="Future Blood Testing Network+":MAILTO:info@futurebloodtesting.org
END:VEVENT
END:VCALENDAR